Fig. 1: BCAT1 expression decreases cisplatin sensitivity.

A qRT-PCR was performed to detect BCAT1 mRNA expression in Hela and HepG2 cells treated with cisplatin. Hela cells were treated with 20 μM cisplatin and HepG2 cells were treated with 10 μM cisplatin for 24 h. B Western blot analysis of BCAT1 and p53 protein expression in Hela and HepG2 cells treated with cisplatin (20 and 10 μM, respectively) for 24 h. C Western blot analysis of BCAT1 protein expression in Hela and HepG2 cell lines. D CCK-8 assays were performed to measure the survival rate of Hela and HepG2 cells treated with different concentrations of cisplatin for 24 h. E A Western blot was used to verify the increased protein level of BCAT1 in Hela cells overexpressing BCAT1. F CCK-8 assays were performed to examine the cytotoxicity in Hela cells overexpressing BCAT1 that were treated with different concentrations of cisplatin for 24 h. G A Western blot was used to verify the decreased protein level of BCAT1 in the BCAT1 knockdown HepG2 cells. H CCK-8 assays were used to examine the cytotoxicity in the BCAT1 knockdown HepG2 cells treated with different concentrations of cisplatin for 24 h. Vec, empty vector; Ctrl, control. Three independent experiments were performed. *P < 0.05, **P < 0.01, ***P < 0.001.